Bidesethyl Chloroquine

Bidesethyl Chloroquine

SCHEMBL6659403

CC(CCCN)Nc1ccnc2cc(Cl)ccc12

nearest known ligand 0.74

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 2/20 0.71
CHRM4 P08173 2/20 0.71
CHRM5 P08912 2/20 0.71
ADRA2A P08913 2/20 0.71
CHRM1 P11229 2/20 0.71
ADRA2B P18089 2/20 0.71
ADRA2C P18825 2/20 0.71
CHRM3 P20309 2/20 0.71
KCNH2 Q12809 2/20 0.71
TMEM97 Q5BJF2 2/20 0.71
SIGMAR1 Q99720 2/20 0.71
ACE2 Q9BYF1 2/20 0.71
NR4A2 P43354 2/20 0.71
CYP2D6 P10635 1/20 0.71
CYP2C19 P33261 1/20 0.71
TDP1 Q9NUW8 1/20 0.71
PRNP P04156 1/20 0.71
APP P05067 1/20 0.71
NQO2 P16083 1/20 0.71
MTOR P42345 1/20 0.71

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bidesethyl Chloroquine SCHEMBL17706108 1.00 CHRM2 (0.71) CHRM2CHRM4CHRM5ADRA2ACHRM1
Bidesethyl Chloroquine SCHEMBL29625380 1.00 CHRM2 (0.71) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL24686036 0.90 CHRM2 (0.74) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL12967486 0.89 CHRM2 (0.77) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL17704778 0.89 CHRM2 (0.77) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL16702858 0.88 CHRM2 (0.75) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL24686033 0.88 CHRM2 (0.74) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL7835332 0.87 NR4A2 (0.70) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL14875102 0.86 CHRM2 (0.70) CHRM2CHRM4CHRM5ADRA2ACHRM1
SCHEMBL28585656 0.86 NR4A2 (0.66) CHRM2CHRM4CHRM5ADRA2ACHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0946744-B1 NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES IDM IMMUNO DESIGNED MOLECULES (FR) 2004-08-18 EP claimed
EP-1135481-B1 NEW OLIGOMERIC CONJUGATES LIABLE TO TRANSFER BIOLOGICAL MOLECULES INTO CELLS IDM IMMUNO DESIGNED MOLECULES (FR) 2004-02-25 EP claimed
US-6372499-B1 TRANSFECTION EFFICIENCY I.D.M. IMMUNO-DESIGNED MOLECULES (FR) 2002-04-16 US claimed
EP-0946744-A1 NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES I.D.M. IMMUNO-DESIGNED MOLECULES (FR) 1999-10-06 EP claimed
WO-1998022610-A1 NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES I.D.M. IMMUNO-DESIGNED MOLECULES (FR) 1998-05-28 WO claimed
WO-2022008597-A1 METHODS AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF INFECTIOUS DISEASES INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2022-01-13 WO disclosed
EP-3892275-A1 AEROSOLIZATION OF HCQ OR ITS METABOLITES FOR THE TREATMENT OF LUNG INFECTIONS INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) 2021-10-13 EP disclosed
WO-2014147531-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER KANDULA MAHESH (IN) 2014-09-25 WO disclosed
WO-2014141057-A2 COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER KANDULA MAHESH (IN) 2014-09-18 WO disclosed
US-7410975-B2 Small molecule toll-like receptor (TLR) antagonists COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-08-12 US disclosed
US-7410975-B2 Small molecule toll-like receptor (TLR) antagonists COLEY PHARMACEUTICAL GROUP, INC. (US) 2008-08-12 US disclosed
US-20070232622-A1 Small molecule toll-like receptor (TLR) antagonists COLEY PHARMACEUTICAL GMBH (DE) 2007-10-04 US disclosed
US-20070232622-A1 Small molecule toll-like receptor (TLR) antagonists COLEY PHARMACEUTICAL GMBH (DE) 2007-10-04 US disclosed
EP-0946744-B1 NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES IDM IMMUNO DESIGNED MOLECULES (FR) 2004-08-18 EP disclosed
EP-1135481-B1 NEW OLIGOMERIC CONJUGATES LIABLE TO TRANSFER BIOLOGICAL MOLECULES INTO CELLS IDM IMMUNO DESIGNED MOLECULES (FR) 2004-02-25 EP disclosed
US-6372499-B1 TRANSFECTION EFFICIENCY I.D.M. IMMUNO-DESIGNED MOLECULES (FR) 2002-04-16 US disclosed
EP-0946744-A1 NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES I.D.M. IMMUNO-DESIGNED MOLECULES (FR) 1999-10-06 EP disclosed
WO-1998022610-A1 NOVEL POLYMERIC COMPLEXES FOR THE TRANSFECTION OF NUCLEIC ACIDS, WITH RESIDUES CAUSING THE DESTABILISATION OF CELL MEMBRANES I.D.M. IMMUNO-DESIGNED MOLECULES (FR) 1998-05-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232622-A1 Small molecule toll-like receptor (TLR) antagonists TLR3, TLR8, TLR7 CHRM2 1453/4885CHRM4 675/4885CHRM5 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.